Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Atricure
Thumbnail
August 17, 2021

Watchman, watch out: Abbott challenges Boston

Thumbnail
August 05, 2021

Atricure’s bizdev decision fails to Amaze

Article image
Vantage logo
July 07, 2021

Smaller medtechs suffer, but not from Covid-19

Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.

Article image
Vantage logo
August 13, 2019

Atricure lassoes Sentreheart for $40m

Ablation company takes on a new tech, and responsibility for an expensive clinical trial.

Article image
Vantage logo
May 11, 2018

Ablation groups scramble to cope with Cabana

The Cabana trial has finally reported, but the data are inconclusive.

Vantage logo
July 06, 2016

Smaller medtechs in charge of their own destiny

Vantage logo
October 30, 2014

Abbott buys into fizzing electrophysiology sector

Vantage logo
August 06, 2014

Medtech employment stable despite harsh environment

Vantage logo
January 14, 2014

Smaller cap medtech firms thrive on takeovers but suffer in court

Vantage logo
January 02, 2014

Medtech news over the Christmas period 2014

Vantage logo
August 23, 2013

Ablation wars heat up as St. Jude buys Endosense

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 12, 2022

Q2 Roundup Infographic

August 10, 2022

Q2 Roundup eBook

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.